首页> 外文期刊>Cell >Requirements for efficient correction of Δf508 CFTR revealed by analyses of evolved sequences
【24h】

Requirements for efficient correction of Δf508 CFTR revealed by analyses of evolved sequences

机译:通过进化序列分析揭示有效校正Δf508CFTR的要求

获取原文
获取原文并翻译 | 示例
           

摘要

Misfolding of ΔF508 cystic fibrosis (CF) transmembrane conductance regulator (CFTR) underlies pathology in most CF patients. F508 resides in the first nucleotide-binding domain (NBD1) of CFTR near a predicted interface with the fourth intracellular loop (ICL4). Efforts to identify small molecules that restore function by correcting the folding defect have revealed an apparent efficacy ceiling. To understand the mechanistic basis of this obstacle, positions statistically coupled to 508, in evolved sequences, were identified and assessed for their impact on both NBD1 and CFTR folding. The results indicate that both NBD1 folding and interaction with ICL4 are altered by the ΔF508 mutation and that correction of either individual process is only partially effective. By contrast, combination of mutations that counteract both defects restores ΔF508 maturation and function to wild-type levels. These results provide a mechanistic rationale for the limited efficacy of extant corrector compounds and suggest approaches for identifying compounds that correct both defective steps.
机译:在大多数CF患者中,ΔF508囊性纤维化(CF)跨膜电导调节剂(CFTR)的折叠错误是病理的基础。 F508位于CFTR的第一个核苷酸结合域(NBD1)与第四个细胞内环(ICL4)的预计界面附近。通过纠正折叠缺陷来鉴定恢复功能的小分子的努力揭示了明显的功效上限。为了理解该障碍物的机理基础,确定了在进化序列中统计上与508偶联的位置,并评估了它们对NBD1和CFTR折叠的影响。结果表明,NBD1折叠和与ICL4的相互作用都被ΔF508突变所改变,并且对任一过程的校正仅部分有效。相比之下,抵消两个缺陷的突变组合可恢复ΔF508成熟并发挥其功能至野生型水平。这些结果为现存的校正剂化合物的有限效力提供了机械原理,并提出了鉴定可校正两个有缺陷步骤的化合物的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号